FDA plans to speed approvals of biosimilars

The Food and Drug Administration on Wednesday unveiled steps to streamline the way it approves lower-cost versions of biologic drugs, in a bid to curb health costs. Why it matters: After years of lagging uptake, biosimilars are gaining traction, especially for cancer and autoimmune conditions. But manufacturers have had to conduct additional research, such as switching studies, in order to deem the treatments interchangeable with the brand-name...